OOIR: Observatory of International Research

Papers

(The TQCC of Clinical Infectious Diseases is 12. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
Subcutaneous and Disseminated Infection in a Renal Transplant Patient	390
IN THE LITERATURE	357
Crude Mortality Associated With the Empirical Use of Polymyxins in Septic Patients in a Setting of High Prevalence of Carbapenem-Resistant Gram-negative Bacteria: Retrospective Analysis of a Cohort	355
A 49-Year-Old Male With Fever and Abdominal Pain	355
Analysis of Repeat Hepatitis C Viremia After Sustained Virologic Response in a Large Cohort of US Veterans	354
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for Human Immunodeficiency Virus Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America an	332
Corrigendum to: Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infections Among Nepalese Children: A Protocol for a Phase III, Randomized Control Trial	331
Correction to: Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America	330
In the Literature	326
Wrong Place at the Wrong Maritime	265
Choosing Wisely: Effectiveness and Safety of Antibiotic Prophylaxis in Close Contacts of Invasive Group A Streptococci Infection	251
Duke-ISCVID Criteria in Patients With Negative Blood Cultures	228
Pre-exposure Prophylaxis for Transgender People: A Systematic Review	195
In The Literature	190
Asymptomatic Malaria Infection and the Immune Response to the 2-Dose Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children	188
The Effectiveness and Safety of Bedaquiline, Pretomanid, and Linezolid (BPaL)–Based Regimens for Rifampicin-Resistant Tuberculosis in Non-Trial Settings—A Prospective Cohort Study in Belarus and Uzbek	174
Primary Care Guidance for Providers Who Care for Persons With Human Immunodeficiency Virus: 2024 Update by the HIV Medicine Association of the Infectious Diseases Society of America	152
Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines: Perceptions and Attitudes From the Food and Drug Administration Public Commentary	145
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial	143
Rectal Culture-Based Versus Empirical Antibiotic Prophylaxis to Prevent Infectious Complications in Men Undergoing Transrectal Prostate Biopsy: A Randomized, Nonblinded Multicenter Trial	141
Embracing Diversity, Equity, and Inclusion: Am I Part of the Picture?	139
How Drivers of Seasonality in Respiratory Infections May Impact Vaccine Strategy: A Case Study in How Coronavirus Disease 2019 (COVID-19) May Help Us Solve One of Influenza’s Biggest Challenges	139
Cluster of Nontoxigenic Corynebacterium diphtheriae Infective Endocarditis and Rising Background C. diphtheriae Cases—Seattle, Washington, 2020–2023	138
Plasma Microbial Cell-free DNA Next-generation Sequencing in the Diagnosis and Management of Febrile Neutropenia	137
Coronavirus Disease 2019 Convalescent Plasma Outpatient Therapy to Prevent Outpatient Hospitalization: A Meta-Analysis of Individual Participant Data From 5 Randomized Trials	133

Coronavirus disease 2019 (COVID-19) Versus Influenza in Hospitalized Adult Patients in the United States: Differences in Demographic and Severity Indicators	127
Mortality From Respiratory Syncytial Virus in Children Under 2 Years of Age: A Prospective Community Cohort Study in Rural Maharashtra, India	125
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection by Intranasal or Intratesticular Route Induces Testicular Damage	124
Circulation of Third-Generation Cephalosporin Resistant Salmonella Typhi in Mumbai, India	114
Clinical Characteristics and Outcomes of Immunocompromised Patients With Coronavirus Disease 2019 Caused by the Omicron Variant: A Prospective, Observational Study	111
Occupations Associated With Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Vaccination, US Blood Donors, May 2021–December 2021	107
Correction to: Stopping Hospital Infections With Environmental Services (SHINE): A Cluster-randomized Trial of Intensive Monitoring Methods for Terminal Room Cleaning on Rates of Multidrug-resistant O	106
Correction to: Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort	106
Correction to: Prevalence of Ocular Complications in Candidemia: Defining the “Battlefield”	105
The Last Mile Problem—Coronavirus Disease 2019 Vaccine Coverage Among the Most Socially Vulnerable	103
Incidence, Attributable Mortality, and Healthcare and Out-of-Pocket Costs of Clostridioides difficile Infection in US Medicare Advantage Enrollees	102
Effective Stakeholder Engagement for Collation, Analysis and Expansion of Antimicrobial Resistance (AMR) Data: A CAPTURA Experience	102
Persistent Severe Acute Respiratory Syndrome Coronavirus 2 Infection With accumulation of mutations in a patient with poorly controlled Human Immunodeficiency Virus infection	99
Severe Acute Respiratory Syndrome Coronavirus 2 Infection Versus Vaccination in Pregnancy: Implications for Maternal and Infant Immunity	98
Reply to Focosi et al	96
Predictors of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Is There a Comprehensive Analysis?	95
Correction to: Increased Peripheral Blood Neutrophil Activation Phenotypes and Neutrophil Extracellular Trap Formation in Critically Ill Coronavirus Disease 2019 Patients: A Case Series and Review of	95
Skin Lesions in an Child with Rhinitis and Painful Paresis	93
Why 2 Studies That Used the Same Probiotic May Have Come Up With Different Outcomes	92
Refractory and Resistant Herpes Simplex Virus Mucocutaneous Infections in Immunocompromised Patients: Literature Review and Proposed Definitions for Use in Clinical Trials	91
Correction to: Impact of Point-of-Care Testing on the Management of Sexually Transmitted Infections in South Africa: Evidence from the HVTN702 Human Immunodeficiency Virus Vaccine Trial	91
Erratum to: Previous Syphilis Alters the Course of Subsequent Episodes of Syphilis	90
Anti-SARS-CoV-2 IgG Antibody Titers in Cotemporary lots of Intravenous Immune Globulin and Fresh Frozen Plasma Compared to COVID Convalescent Plasma	90
Study Design and Methodology of Antibiotic Duration in Hematological Patients With Pseudomonas aeruginosa Bloodstream Infection	89
Safety and Efficacy of 3 Alternative Regimens Against Relapsing Plasmodium vivax Malaria in Glucose 6-Phosphate Dehydrogenase–Deficient Patients in the Brazilian Amazon (ALTPRIM)	89
Natural Antibodies and Severe Acute Respiratory Syndrome Coronavirus 2–Specific Antibodies in Healthy Asymptomatic Individuals	88
Correction to: Serological Profiling of Group A Streptococcus Infections in Acute Rheumatic Fever	88
Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Kinetics and Protection Duration	88
Correction to: Prediction of HIV Drug Resistance Based on Virologic, Immunologic, Clinical, and/or Adherence Criteria in the Stratall ANRS 12110/ESTHER Trial in Cameroon	88
A Middle-Aged Man With Skin Lesions, Progressive Deterioration of Renal Function, and Pulmonary Cheerios	85
Corrigendum to: Toxoplasmosis Outbreak Associated With Toxoplasma gondii-Contaminated Venison—High Attack Rate, Unusual Clinical Presentation, and Atypical Genotype	85
Correction to: Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant Tuberculosis	84
Pathology and Pathogenesis of Lassa Fever: Novel Immunohistochemical Findings in Fatal Cases and Clinico-pathologic Correlation	84
In the Literature	83
Antibiotic Treatment Duration for Community-Acquired Pneumonia in Children in High-Income Countries—GRADE Issues	82
Exposure Outcomes in Fully Vaccinated Healthcare Personnel With Known Severe Acute Respiratory Syndrome Coronavirus 2 Exposure—Minnesota, January–August 2021	82
In the Literature	80
Endocarditis Caused by Nontypeable Streptococcus pneumoniae	76
Collecting Multi-country Retrospective Antimicrobial Consumption and Use Data: Challenges and Experience	76
Broadly Neutralizing Antibodies for Human Immunodeficiency Virus Treatment: Broad in Theory, Narrow in Reality	76
Probable Animal-to-Human Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Delta Variant AY.127 Causing a Pet Shop-Related Coronavirus Disease 2019 (COVID-19) Outbreak in Ho	75
Extensively Drug-Resistant Pseudomonas aeruginosa Outbreak Associated With Artificial Tears	74
The Influence of Rapid Influenza Diagnostic Testing on Clinician Decision-Making for Patients With Acute Respiratory Infection in Urgent Care	74
The use of Vaccinia Immune Globulin in the Treatment of Severe Mpox. Virus Infection in Human Immunodeficiency Virus/AIDS	74
Comparative Effectiveness of BNT162b2 and mRNA-1273 Booster Dose After BNT162b2 Primary Vaccination Against the Omicron Variants: A Retrospective Cohort Study Using Large-Scale Population-Based Regist	73
Chronic Aichi Virus Infection As a Cause of Long-Lasting Multiorgan Involvement in Patients With Primary Immune Deficiencies	73
The Real Crisis in Antimicrobial Resistance: Failure to Anticipate and Respond	72
Preserving the Future of Infectious Diseases: Why We Must Address the Decline in Compensation for Clinicians and Researchers	72
Are Contact Precautions “Essential” for the Prevention of Healthcare-associated Methicillin-Resistant Staphylococcus aureus?	72
Corrigendum to: Correlation Between 3790 Quantitative Polymerase Chain Reaction–Positives Samples and Positive Cell Cultures, Including 1941 Severe Acute Respiratory Syndrome Coronavirus 2 Isolates	71

Single Monoclonal Antibodies Should Not Be Used for COVID-19 Therapy: A Call for Antiviral Stewardship	71
Correction to: IWGDF/IDSA Guidelines on the Diagnosis and Treatment of Diabetes-related Foot Infections (IWGDF/IDSA 2023)	71
A Nasty Human Immunodeficiency Virus Type 1 (HIV-1) Variant	71
2024 Clinical Practice Guideline Update by the Infectious Diseases Society of America on Complicated Intra-abdominal Infections: Risk Assessment, Diagnostic Imaging, and Microbiological Evaluation in	71
Subclinical Tuberculosis in Children: Diagnostic Strategies for Identification Reported in a 6-year National Prospective Surveillance Study	71
Correction to: Clinical Experience With Severe Acute Respiratory Syndrome Coronavirus 2–Related Illness in Children: Hospital Experience in Cape Town, South Africa	71
Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Clusters Based on Integrated Genomic Surveillance, Outbreak Analysis and Contact Tracing in an Urban Setting	69
Educational Impact of #IDJClub, a Twitter-Based Infectious Diseases Journal Club	69
Fosfomycin Vs Ciprofloxacin as Oral Step-Down Treatment for Escherichia coli Febrile Urinary Tract Infections in Women: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial	69
Correction to: Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Val	68
Reply to Ito	68
Review Article: Gastroenterology and Clostridium difficile Infection: Past, Present, and Future	67
Excess Invasive Meningococcal Disease Associated With Seasonal Influenza, South Africa, 2003–2018	66
Correction to: Epidemiology and Outcome of Fungemia in a Cancer Cohort of the Infectious Diseases Group (IDG) of the European Organization for Research and Treatment of Cancer (EORTC 65031)	66
Reply to van Crevel, et al	66
Correction to: Capturing Data on Antimicrobial Resistance Patterns and Trends in Use in Regions of Asia (CAPTURA) Supplement	66
Withdrawn as duplicate: Cover image/text	65
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission Associated With an Indoor Music Event That Required Proof of Full Vaccination Against Coronavirus Disease 2019 (COVID-19) Prio	65
Regulatory Level of Evidence and Practicality in Antifungal Use Decisions for Less Common Fungal Diseases	64
Medicare Prescription Plans Limit Access to Recommended Drugs for Clostridioides difficile Infection	63
In the Literature	63
Correction to: Sulopenem or Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Phase 3, Randomized Trial	63
In the Literature	63
In the Literature	62
In the Literature	62
Reply to Swindells et al	62
Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 Outcomes in Organ Transplant Recipients During the Omicron Wave	61
It’s Hard to Measure Success While Caring for Surges in Coronavirus Disease 2019 (COVID-19) Hospitalizations	61
Treatment Outcomes After Offering Same-Day Initiation of Human Immunodeficiency Virus Treatment—How to Interpret Discrepancies Between Different Studies	61
Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study	61
Increased Peripheral Blood Neutrophil Activation Phenotypes and Neutrophil Extracellular Trap Formation in Critically Ill Coronavirus Disease 2019 (COVID-19) Patients: A Case Series and Review of the	60
Influenza Hospitalization Burden by Subtype, Age, Comorbidity, and Vaccination Status: 2012–2013 to 2018–2019 Seasons, Quebec, Canada	60
Cognitive Impairment in Tuberculous Meningitis	59
Breastfeeding Among People With Human Immunodeficiency Virus in North America: A Multisite Study	59
Recent Hybrid Plasma Better Neutralizes Omicron Sublineages Than Old Hyperimmune Serum	58
First Case of Lethal Encephalitis in Western Europe Due to European Bat Lyssavirus Type 1	58
Executive Summary: State-of-the-Art Review: State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms	58
Cluster ofBurkholderia cepaciaComplex Infections Associated With Extracorporeal Membrane Oxygenation Water Heater Devices	58
In Memoriam: Sherwood Leslie Gorbach, MD	58
Persistence of Severe Acute Respiratory Syndrome Coronavirus 2 to Explain Long Coronavirus Disease 2019 Is Not Consistent With the Available Data	58
Neonatal Paenibacilliosis: Paenibacillus Infection as a Novel Cause of Sepsis in Term Neonates With High Risk of Sequelae in Uganda	58
Concordance of Noninvasive Plasma Cell-free DNA With Invasive Diagnostics for Diagnosis of Invasive Fungal Disease	57
Effects of Treatment of Coronavirus Disease 2019 With Convalescent Plasma in 25 B-Cell–Depleted Patients	57
Correction to: A Randomized Controlled Trial of Efficacy and Safety of Fecal Microbiota Transplant for Preventing Recurrent Clostridioides difficile Infection	57
Question of Whether Tenofovir Disoproxil Fumarate/Emtricitabine Provides Protection Against Clinical Severity of Coronavirus Disease 2019	56
Confirmed Case of Longstanding Respiratory Francisella tularensis holarctica Infection: Nebraska, 2022	56
mRNA Vaccine-Elicited Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific T Cells Persist at 6 Months and Recognize the Delta Variant	56
Reduced Odds of Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection After Vaccination Among New York City Adults, July 2021–November 2021	55
Lack of Access to Coronavirus Disease 2019 Vaccines Could Be a Greater Threat than Vaccine Hesitancy in Low-Income and Conflict Nations: The Case of Yemen	55
Sexually Transmitted Infection/Human Immunodeficiency Virus (STI/HIV) Testing, STIs, and HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in the	55
Class-Specific Relationship Between Use of Immunosuppressants and Risk for Community-Acquired Clostridioides difficile Infection	55
A Painful Breast Mass	55
A 35-Year-Old Immunocompromised Male With Epigastric Pain	55
Evaluating the Approach for Gram-Negative Bacteremia and Fungemia in Cardiovascular Implantable Electronic Device Infections From a Recent Infectious Diseases Society of America Guideline on Advanced	54
In the Literature	54
Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial	54
Quantitative Microbial Cell-Free DNA Sequencing from Plasma: A Potential Biomarker for the Diagnosis of Staphylococcal Infection of Cardiac Implantable Electronic Devices	54
COVID-19 Antiviral Medication Use Among Pregnant and Recently Pregnant US Outpatients	54
Long-acting injectable HIV therapy outcomes among persons with HIV who have adherence challenges to oral antiretroviral therapy	53
Development and Evaluation of a Novel Algorithm to Identify Doxy-PEP Users at a Large Healthcare System in the Bronx, New York	53
PROCESS Trial: Effect of Duloxetine Premedication for Postherpetic Neuralgia Within 72 Hours of Herpes Zoster Reactivation—A Randomized Controlled Trial	53
Validation of the proposed definition for complicated coagulase negative staphylococcal bacteremia	53
Ivermectin for the Treatment of Coronavirus Disease 2019: A Systematic Review and Meta-analysis of Randomized Controlled Trials	52
Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study	52
Undetected and Relatively Sustained Severe Acute Respiratory Syndrome Coronavirus 2 Circulation Worldwide During 2019	50
Predictors of Mortality of Streptococcal Bacteremia and the Role of Infectious Diseases Consultation: A Retrospective Cohort Study	50
Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial	50
Long-term Real-world Protection Afforded by Third mRNA Doses Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections, Coronavirus Disease 19-related Emergency Attendances and Ho	50
Strengths and Challenges of Various Models of Geriatric Consultation for Older Adults Living With Human Immunodeficiency Virus	50
Audit and Feedback Interventions for Antibiotic Prescribing in Primary Care: A Systematic Review and Meta-analysis	49
Long-Acting Cabotegravir and Rilpivirine: Innovation, New Challenges, and Opportunities	49
Treatment Responses to Integrase Strand-transfer Inhibitor-containing Antiretroviral Regimens in Combination With Short-course Rifapentine-based Regimens for Latent Tuberculosis Infection Among People	49
Microbial Cell-Free DNA Identifies the Causative Pathogen in Infective Endocarditis and Remains Detectable Longer Than Conventional Blood Culture in Patients with Prior Antibiotic Therapy	49
Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVIC	49
Weight Gain After Antiretroviral Therapy Initiation and Subsequent Risk of Metabolic and Cardiovascular Disease	48
Retrospective Multicenter Study Comparing Infectious and Noninfectious Aortitis	48
Persistent Coronavirus Disease 2019 (COVID-19) in an Immunocompromised Host Treated by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Monoclonal Antibodies	48
Assessment of the Impact of RNase in Patients With Severe Fatigue Related to Post-Acute Sequelae of SARS-CoV-2 Infection: A Randomized Phase 2 Trial of RSLV-132	48
Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2–Naive Residents of Nursing Homes	48
Follow-up Fungal Polymerase Chain Reaction (PCR) Testing on Plasma and Bronchoalveolar Lavage (BAL) Fluid Is Low Yield	47

Impact of Anti-CD4 Autoantibodies on Immune Reconstitution in People With Advanced Human Immunodeficiency Virus	47
Long-Acting Cabotegravir Plus Rilpivirine in People With Human Immunodeficiency Virus With Adherence Challenges and Viremia: Current Data and Future Directions	47
Influenza Vaccine Effectiveness Against Illness and Asymptomatic Infection in 2022–2023: A Prospective Cohort Study	47
T-SPOT.TB Reactivity in Southern African Children With and Without in Utero Human Immunodeficiency Virus Exposure	47
Predicting Pediatric Tuberculosis: The Need for Age-Specific Host Biosignatures	47
Case Investigation and Contact Tracing Efforts From Health Departments in the United States, November 2020 to December 2021	46
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)	46
Alpha Variant Coronavirus Outbreak in a Nursing Home Despite High Vaccination Coverage: Molecular, Epidemiological, and Immunological Studies	46
Middle East Respiratory Syndrome Coronavirus Infection Elicits Long-lasting Specific Antibody, T and B Cell Immune Responses in Recovered Individuals	46
Is Inhaled Zanamivir Non-inferior to Oral Oseltamivir in the Treatment of Outpatients With Influenza?	46
Shorter Versus Longer Course of Antibiotic Therapy for Gram-Negative Bacteremia: Time for a Tailored Duration?	46
Breastfeeding in the United States Among Women With HIV: Con Viewpoint	45
Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations	45
Reconciling Egg- and Antigen-Based Estimates of Schistosoma mansoni Clearance and Reinfection: A Modeling Study	44
Reply to Bailly et al	44
Impact of Revised Diagnostic Testing Algorithms and Case Definitions on Lyme Disease Surveillance in a Low-Incidence State: An Interrupted Time Series Analysis	44
Reply to Peluso et al	44
Associations Between Findings of Fusobacterium necrophorum or β-Hemolytic Streptococci and Complications in Pharyngotonsillitis—A Registry-Based Study in Southern Sweden	44
Invasive Listeriosis in Southern Switzerland: A Local Problem That Is Actually Global	44
Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era	44
Trajectories of Pre-exposure Prophylaxis Adherence Among Commercially Insured Individuals	44
Oral Fluoroquinolone Use and the Risk of Acute Liver Injury: A Nationwide Cohort Study	44
Reply to Hagiya et al	43
Switch to Integrase Strand Transfer Inhibitors During the Menopausal Transition Is Associated With Accelerated Body Composition Change in Women With Human Immunodeficiency Virus	43
High-Quality Large-Scale Clinical Studies on Brain Abscess: Finally!	43
A Silver Woman	43
Cytomegalovirus Seroprevalence Among US Children Aged 1 to 5 Years: The National Health and Nutrition Examination Surveys, 2017–March 2020 Pre-Pandemic Dataset	43
Association of Virus Variation and Vaccination Status With Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection	42
Cryptic Plasmodium inui and Plasmodium fieldi Infections Among Symptomatic Malaria Patients in Thailand	42
Human Immunodeficiency Virus-1 Viremia and Cancer Risk in 2.8 Million People: The South African HIV Cancer Match Study	42
Seroprevalence and Risk Factors for Severe Acute Respiratory Syndrome Coronavirus 2 Among Incarcerated Adult Men in Quebec, Canada, 2021	42
Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Immunogenicity and Reactogenicity	42
Effectiveness of Beta-Lactam plus Doxycycline for Patients Hospitalized with Community-Acquired Pneumonia	42
Incidence and Predictors of Community-Acquired Pneumonia in Patients With Hematological Cancers Between 2016 and 2019	42
Rapid Control of Hospital-Based Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Clusters Through Daily Testing and Universal Use of N95 Respirators	41
Reply to He et al: Established Association Between Glycemic Control and Anti-Tuberculosis Drug Exposures After Controlling Confounding Effects	41
Reply to Klein and Harris	41
Reply to Adelman et al	41
Differences in Post-mRNA Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Immunoglobulin G (IgG) Concentrations and Surrogate Virus Neutralization Test Response by Human Immuno	41
Several Concerns With Doxycycline Meta-Analysis	41
Noninferiority Study of Purified Vero Rabies Vaccine—Serum Free in 3-dose and 2-dose Preexposure Prophylaxis Regimens in Comparison With Licensed Rabies Vaccines	41
Isolation and Quarantine for Coronavirus Disease 2019 in the United States, 2020–2022	40
High-level Colonization With Antibiotic-Resistant Enterobacterales Among Individuals in a Semi-Urban Setting in South India: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study	40
Controlled Human Infection Model for Hepatitis C Virus Vaccine Development: Is It Time to Be Real?	40
Relationship Between Acute SARS-CoV-2 Viral Clearance and Long COVID-19 (Long COVID) Symptoms: A Cohort Study	40
Maternal Colonization Versus Nosocomial Transmission as the Source of Drug-Resistant Bloodstream Infection in an Indian Neonatal Intensive Care Unit: A Prospective Cohort Study	40
Antiviral Use Among Children Hospitalized With Laboratory-Confirmed Influenza Illness: A Prospective, Multicenter Surveillance Study	39
Quantifying Environmental Mitigation of Aerosol Viral Load in a Controlled Chamber With Participants Diagnosed With Coronavirus Disease 2019	39
Performance of a Histidine Rich Protein-2 Based (First Response) and a p-Lactate Dehydrogenase-based (Optimal) Rapid Diagnostic Test for Diagnosis of Malaria in Patients With Pediatric Sickle Cell Dis	38
Population Mobility and Aging Accelerate the Transmission of Coronavirus Disease 2019 in the Deep South: A County-Level Longitudinal Analysis	38
Lower Prevalence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among People Experiencing Homelessness Tested in Outdoor Encampments Compared With Overnight Shelters: Denver	38
Vitamin C Urinary Loss and Deficiency in Human Immunodeficiency Virus (HIV): Cross-sectional Study of Vitamin C Renal Leak in Women With HIV	38
The Current and Future State of Vaccines for Lyme Disease	38
Epidemiology and Outcomes of Antibiotic De-escalation in Patients With Suspected Sepsis in US Hospitals	38
Safety of Streptococcus pyogenes Vaccines: Anticipating and Overcoming Challenges for Clinical Trials and Post-Marketing Monitoring	38
Refining Reproduction Number Estimates to Account for Unobserved Generations of Infection in Emerging Epidemics	37
Effectiveness of BNT162b2 and mRNA-1273 Second Doses and Boosters for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and SARS-CoV-2–Related Hospitalizations: A Statewide Report	37
Cumulative Incidence and Risk Factors for Severe Coronavirus Disease 2019 in French People With Cystic Fibrosis	37
Geographical Differences in the Self-Reported Functional Impairment of People With Human Immunodeficiency Virus (HIV) and Associations With Cardiometabolic Risk	37
Independent FDA Analyses of Nirmatrelvir/Ritonavir Resistance in the Phase 2/3 Trials EPIC-HR and EPIC-SR	37
Go V.I.R.A.L.: Social Media Engagement Strategies in Infectious Diseases	37
Immunological Monitoring in Hepatitis C Virus Controlled Human Infection Model	37
Infective Endocarditis Among High-risk Individuals Before and After the Cessation of Antibiotic Prophylaxis in Dentistry: A National Cohort Study	36
Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network	36
Attributable Mortality of Candida Bloodstream Infections in the Modern Era: A Propensity Score Analysis	36
Dolutegravir-based Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 (HIV-2) Infection: Progress for People With HIV-2	36
The Effect of a Second Dose of Measles Vaccine at 18 Months of Age on Nonaccidental Deaths and Hospital Admissions in Guinea-Bissau: Interim Analysis of a Randomized Controlled Trial	36
Within-Host Dynamics and Duration of Colonization of Travel-Acquired Multidrug-Resistant Enterobacterales in Untreated Individuals	36
Reply to Fernández-de-las-Peñas	36
Delayed Mortality Among Solid Organ Transplant Recipients Hospitalized for COVID-19	35
Timing and Predictors of Loss of Infectivity Among Healthcare Workers With Mild Primary and Recurrent COVID-19: A Prospective Observational Cohort Study	35
Caveats for Validating the Diagnostic Accuracy of Diagnostic or Classification Criteria for Infective Endocarditis	35
Validation of ISARIC 4C Mortality and Deterioration Scores in a Mixed Vaccination Status Cohort of Hospitalized Coronavirus Disease 2019 (COVID-19) Patients in Singapore	35
Evaluating the Benefits and Risks of Ex Vivo Liver Resection and Autotransplantation in Treating Hepatic End-stage Alveolar Echinococcosis	35
High Intrapulmonary Rifampicin and Isoniazid Concentrations Are Associated With Rapid Sputum Bacillary Clearance in Patients With Pulmonary Tuberculosis	35
A Generalizable Risk Factor: Socioeconomic Status and Multiresistant Organism Colonization	35
Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron and Other Variants in Serum From Children With Vaccination-Induced Myocarditis	35
Extracorporeal Membrane Oxygenation–Dependent Fulminant Melioidosis From Caspase 4 Mutation Reversed by Interferon Gamma Therapy	35
Prevention of Typhoid by Vi Conjugate Vaccine and Achievable Improvements in Household Water, Sanitation, and Hygiene: Evidence From a Cluster-Randomized Trial in Dhaka, Bangladesh	35
Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Health	35
Genomic Insights Into the Mechanism of Carbapenem Resistance Dissemination in Enterobacterales From a Tertiary Public Heath Setting in South Asia	34
A Retrospective Database Analysis of Before and After Social Distancing in Relation to Pediatric Infection Rate and Healthcare Services Usage During the Coronavirus Disease 2019 Pandemic	34
Out-of-Hospital Cardiac Arrest in Individuals With Human Immunodeficiency Virus: A Nationwide Population-Based Cohort Study	34
Enhanced Infection Prevention Measures Including Universal N95 Usage and Daily Testing: The Impact on SARS-CoV-2 Transmission in Cohorted Hospital Cubicles Through Successive Delta and Omicron Waves	34
The Urgent Need to Implement Point-of-Care RNA Testing for Hepatitis C Virus to Support Elimination	34
Global Epidemiology of Human Infections With Variant Influenza Viruses, 1959–2021: A Descriptive Study	34
Population-Weighted Seroprevalence From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Vaccination, and Hybrid Immunity Among US Blood Donations From January to December 2021	34
Stewardship in Brazil: A Call for Action	34
Therapeutic Phage Monitoring: A Review	34
State of the Management of Infections Caused by Multidrug-Resistant Gram-Negative Organisms	34
Reply to Chang et al	34
Cefazolin for the Treatment of Central Nervous System Infections	34
Unmasking Pneumococcal Carriage in a High Human Immunodeficiency Virus (HIV) Prevalence Population in two Community Cohorts in South Africa, 2016–2018: The PHIRST Study	34
Group B Streptococcus Infection in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years	34
Prevalence, Risk Factors, and Shedding of Human Herpes Virus-8 Among Men Having Sex With Men Enrolled in a Pre-exposure Prophylaxis Study	34